Loading...
XSHE
003017
Market cap315mUSD
Jul 18, Last price  
27.25CNY
1D
-1.80%
1Q
33.91%
IPO
-40.36%
Name

Zhejiang Dayang Biotech Group Co Ltd

Chart & Performance

D1W1MN
P/E
45.23
P/S
2.46
EPS
0.60
Div Yield, %
1.65%
Shrs. gr., 5y
14.02%
Rev. gr., 5y
9.50%
Revenues
919m
-13.10%
499,724,931458,565,579448,098,833441,234,459554,719,478584,159,118621,750,703678,335,140783,209,2771,058,104,944919,451,375
Net income
50m
-38.05%
26,321,79928,071,64623,666,15528,815,47150,256,35570,796,60279,497,18391,606,02670,009,32380,726,94850,006,704
CFO
182m
+98.53%
91,644,61957,730,23148,950,95984,631,60048,638,31538,774,402113,092,957112,488,116091,886,561182,422,543
Dividend
Jul 11, 20240.45 CNY/sh

Profile

Zhejiang Dayang Biology Technology Co.,Ltd. engages in research and development, production, and sale of biological products, agricultural chemicals, and chemical in China and internationally. The company's products include food additive potassium carbonate, potassium carbonate, food additive potassium bicarbonate, potassium bicarbonate, agricultural grade ammonium chloride, and industrial grade ammonium chloride. It also offers chemical products, such as 2-chloro-6-fiuorobenzaldehyde, 2-chloro-6-fluorobenzyl chloride, and anisole products; veterinary APIs, including amprolium HCL; and veterinary drug premixes comprising enramycin premixes. The company was founded in 1976 and is based in Jiande, China.
URL
http://www.dyhg.com/
IPO date
Oct 26, 2020
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122016‑00
Income
Revenues
919,451
-13.10%
1,058,105
35.10%
Cost of revenue
867,494
968,288
Unusual Expense (Income)
NOPBT
51,958
89,817
NOPBT Margin
5.65%
8.49%
Operating Taxes
(3,020)
Tax Rate
NOPAT
54,978
89,817
Net income
50,007
-38.05%
80,727
15.31%
Dividends
(42,607)
(34,320)
Dividend yield
2.17%
1.52%
Proceeds from repurchase of equity
(1)
BB yield
0.00%
Debt
Debt current
180,435
282,143
Long-term debt
69,934
Deferred revenue
11,353
11,961
Other long-term liabilities
1
1
Net debt
(186,838)
(145,446)
Cash flow
Cash from operating activities
182,423
91,887
CAPEX
(103,627)
Cash from investing activities
145,084
Cash from financing activities
(75,675)
16,871
FCF
68,281
50,152
Balance
Cash
382,366
427,589
Long term investments
54,840
Excess cash
391,234
374,684
Stockholders' equity
521,719
492,212
Invested Capital
877,822
889,469
ROIC
6.22%
10.61%
ROCE
4.01%
6.93%
EV
Common stock shares outstanding
80,734
81,542
Price
24.32
-12.23%
27.71
-33.71%
Market cap
1,963,453
-13.10%
2,259,539
-35.65%
EV
1,776,616
2,114,093
EBITDA
121,632
150,067
EV/EBITDA
14.61
14.09
Interest
6,680
5,478
Interest/NOPBT
12.86%
6.10%